Nasdaq
$4.88▼ 3.17%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $345.7MShares out 70.8M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
7- 10.6After-hours26.10.07 05:004Ownership#●●●
YD Bio Ltd
YD Bio Ltd insider Chang Kochi filed a Form 4 statement regarding changes in beneficial ownership of securities as of September 30, 2026. This filing serves to disclose the updated equity holdings of the reporting insider to the market.…more
$4.88-3.17%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 10.6After-hours26.10.07 05:004Ownership
YD Bio Ltd
Insider Lu Shao-Ta of YD Bio Ltd has reported their beneficial ownership of securities as of September 30, 2026. This filing serves as a formal disclosure of changes in insider holdings via Form 4.…more
$4.88-3.17%vs prev closeView filingShare - 9.16After-hours26.09.17 05:014Ownership
YD Bio Ltd
Dr. Ethan Shen, an insider and reporting person for YD Bio Ltd, filed a Form 4 on September 16, 2026, to report changes in beneficial ownership of securities as of September 14, 2026. This filing formalizes the update regarding the insider's equity holdings.…more
$4.88-3.17%vs prev closeView filingShare
6 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 5d agoPre-market26.10.20 21:00#●●●#●●●#●●●
YD Bio Partners with JoiiUp for AI-Driven Cancer Risk Assessment
YD Bio is integrating its AI-based cancer risk assessment tool into JoiiUp’s corporate wellness platform to provide personalized health insights. The tool is intended for risk stratification rather than medical diagnosis, and the financial impact of this partnership remains unquantified.…more
$4.88-3.17%vs prev closeDetected5m · 30m · 60m · Next dayPLUS
- 8.31After-hours26.09.01 07:00
●●●●●●●● ●●●●● ●●●●●●
YD Bio reported a 315% increase in revenue for the first half of 2026, though net income was driven primarily by non-cash warrant liability adjustments. Excluding these items, the company's operational net loss actually widened to $3.1 million, indicating ongoing challenges in core profitability.…more
$4.88-3.17%vs prev close - 8.25Pre-market26.08.25 21:03
●●●●●●●● ●●●●● ●●●●●●
YD Bio announced the publication of a peer-reviewed review article in the journal Nutrients exploring the relationship between lipid-soluble nutrients and the heart-brain-bone axis. The study was conducted in collaboration with various medical institutions but does not represent a direct commercial or financial milestone.…more
$4.88-3.17%vs prev closeShareBenzinga
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report